All Releases
 |
Athersys Announces Positive Results from Phase I Study of Multistem(R) in Heart Attack Patients
Jul 28, 2010
|
20.0 KB |
|
| |
CLEVELAND, Jul 28, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) announced today positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results...
|
|
Athersys to Host Conference Call to Announce Phase I Clinical Trial Results Involving MultiStem(R) for Acute Myocardial Infarction
Jul 28, 2010
|
11.1 KB |
|
| |
CLEVELAND, Jul 28, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) announced it will host a conference call today at 4:30 PM (Eastern Time) to review the top-line data results of the phase I clinical trial of MultiStem(R), its cell therapy treatment for individuals following AMI (or heart attack).
Gil Van Bokkelen, ...
|
|
Athersys to Host Second Quarter Financial Results Call
Jul 6, 2010
|
10.1 KB |
|
| |
CLEVELAND, Jul 6, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its second quarter 2010 financial results at approximately 4:00 PM Eastern Time on Monday, August 9, 2010, and host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chair...
|
|
Athersys and CSCRM Receive Grant Funding to Support Research Into Novel Stem Cell Treatment of Spinal Cord Injury
Jun 25, 2010
|
14.6 KB |
|
| |
CLEVELAND, Jun 25, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) and its collaborators, including the Center for Stem Cell and Regenerative Medicine (CSCRM) and Case Western Reserve University (CWRU), announced today that they have been awarded $1 million through the Ohio Third Frontier Biomedical Program to support r...
|
|
Athersys Elects Jack Wyszomierski to Board of Directors
Jun 21, 2010
|
12.6 KB |
|
| |
CLEVELAND, Jun 21, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced that Jack L. Wyszomierski has been elected to the Board of Directors at its annual meeting of shareholders held on June 17, 2010. Jordan S. Davis and William C. Mulligan did not stand for re-election.
"I want to welcome Jack to our bo...
|
|
Athersys to Present at the Rodman and Renshaw 6th Annual Global Healthcare Conference
May 17, 2010
|
10.1 KB |
|
| |
CLEVELAND, May 17, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will present at the Rodman and Renshaw 6th Annual Global Healthcare Conference, to be held May 16-18, 2010 at The Grosvenor House Hotel, London, UK.
William (B.J.) Lehmann, President and Chief Operating Officer, will present on Tue...
|
|
Athersys Presents New Data and Advancements in Stem Cell and Drug Development Programs at Annual R&D Day
May 14, 2010
|
19.3 KB |
|
| |
NEW YORK and CLEVELAND, May 14, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today presented data supporting its MultiStem(R) programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the ar...
|
|
Athersys Reports First Quarter 2010 Results
May 6, 2010
|
19.7 KB |
|
| |
CLEVELAND, May 6, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the quarter ended March 31, 2010.
First Quarter and Recent Highlights Include:
-- Commenced preclinical development activities in collaboration with
Pfizer to develop MultiStem(R), our patented...
|
|
Athersys to Host First Quarter Financial Results Call
Apr 29, 2010
|
10.1 KB |
|
| |
CLEVELAND, Apr 29, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its first quarter financial results at approximately 4:00 p.m. Eastern Time (ET) on Thursday, May 6, 2010, and host a conference call shortly thereafter at 4:30 p.m. ET to review the results. Gil Van Bokkelen, Chairman and...
|
|
Athersys to Host Second Annual Investor/ Research & Development Day
Apr 20, 2010
|
14.8 KB |
|
| |
CLEVELAND, Apr 20, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will host its second annual Investor/Research & Development Day being held at the Intercontinental Hotel on Friday, May 14, 2010 in New York City. The meeting will begin promptly at 8:30 a.m. Eastern Time and end at approximately 11:30...
|
|
Athersys Reports Fourth Quarter and 2009 Annual Results
Mar 11, 2010
|
20.0 KB |
|
| |
CLEVELAND, Mar 11, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the fourth quarter of 2009 and for the year ended December 31, 2009.
Fourth Quarter and Recent Highlights Include:
-- Entered global collaborative agreement with Pfizer to develop and market
M...
|
|
Athersys to Host Fourth Quarter Financial Results Call
Feb 25, 2010
|
9.8 KB |
|
| |
CLEVELAND, Feb 25, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its fourth quarter 2009 financial results at approximately 4:00 PM (Eastern Time) on Thursday, March 11, 2010, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkelen...
|
|
Athersys Announces Completion of Patient Enrollment in Phase I Study of Multistem(R) in Acute Myocardial Infarction
Feb 16, 2010
|
13.7 KB |
|
| |
CLEVELAND, Feb 16, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced that it has completed patient enrollment for its phase I clinical trial of MultiStem(R), its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a hea...
|
|
Athersys Receives U.S. Patent Covering Adult Stem Cell Composition & Production
Feb 10, 2010
|
13.0 KB |
|
| |
CLEVELAND, Feb 10, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has been granted U.S. patent 7,659,118 that covers non-embryonic multipotent stem cells, their isolation and expansion, and related pharmaceutical compositions. Athersys also announced that it has been granted -- and the oppositio...
|
|
Athersys to Present at 12th Annual BIO CEO & Investor Conference
Feb 2, 2010
|
11.1 KB |
|
| |
CLEVELAND, Feb 2, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel, February 8-9, 2010, in New York City. The conference will provide a forum to discuss breakthrough therapeutic developments and i...
|
|
Athersys Files Shelf Registration Statement
Jan 14, 2010
|
11.2 KB |
|
| |
CLEVELAND, Jan 14, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has filed a shelf registration statement with the Securities and Exchange Commission ("SEC"). Athersys currently does not have any immediate plans to offer or sell the securities under this registration statement. The registration...
|
|
Athersys Enters Into Global Agreement With Pfizer to Develop and Market MultiStem(R) for the Treatment of Inflammatory Bowel Disease
Dec 21, 2009
|
13.6 KB |
|
| |
CLEVELAND, Dec 21, 2009 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has entered into an agreement with Pfizer Inc. (PFE) to develop and commercialize MultiStem(R) for the treatment of Inflammatory Bowel Disease ("IBD"). MultiStem is an investigational stem cell therapy currently in development by ...
|
|
Athersys Reports 2009 Third Quarter Results
Nov 5, 2009
|
16.7 KB |
|
| |
CLEVELAND, Nov 5, 2009 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the quarter ended September 30, 2009. Third Quarter Highlights Include:
* Continued enrollment in two MultiStem(R) phase I clinical trials
for patients who suffer an acute myocardial infarction (AMI...
|
|
Athersys to Host Third Quarter 2009 Financial Results Call
Oct 20, 2009
|
10.0 KB |
|
| |
CLEVELAND, Oct 20, 2009 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its third quarter 2009 financial results at approximately 4:00 PM (Eastern Time) on Thursday, November 5, 2009, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkele...
|
|
Athersys Reports 2009 Second Quarter Results
Aug 6, 2009
|
17.3 KB |
|
| |
CLEVELAND, Aug 6, 2009 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the quarter ended June 30, 2009.
Second Quarter Highlights Include:
-- Continued enrollment in two MultiStem(r) phase I clinical trials,
for patients who suffer an acute myocardial infarction...
|
|
|
0.14 
